Navigation Links
Actor Rob Brown Rushes to Gain Ground Against Blood Cancer
Date:3/3/2008

Star of Upcoming Universal Pictures' Drama The Express Named National Spokesperson for The Leukemia & Lymphoma Society's 2008 Light The Night

Walk

WHITE PLAINS, N.Y., March 3 /PRNewswire/ -- Rob Brown, who stars in the upcoming drama The Express as Ernie Davis, a 1960s football hero who battled leukemia and became the first African-American to win the Heisman Trophy, is the national spokesperson for The Leukemia & Lymphoma Society's (LLS) 2008 Light The Night(R) Walk, an annual event that raises critical funds for research and patient services, and honors lives touched by blood cancer. The film is scheduled for release on Oct. 3, 2008.

Raised in poverty in Pennsylvania coal-mining country, Davis overcame seemingly insurmountable obstacles to become an unstoppable running back for the Syracuse University Orangemen. Following his draft to play for the Cleveland Browns, tragedy struck the athlete and he was never able to take the professional field. In 1963, Davis died of leukemia, but his legacy of smashing barriers on and off the playing field lives on.

"Ernie Davis's dreams were cut short by leukemia at the age of 23," said Brown. "Playing the role of Davis has helped me understand that all blood cancer patients deserve to live better, longer lives and that supporting research to help make cures happen is crucial."

As national spokesperson for the 2008 Walk, Brown has filmed a public service announcement and lent his image to brochures, posters and other publicity materials. Brown earned renown for his starring role in the 2000 film Finding Forrester. He will next appear in March's Stop Loss, a drama about young soldiers who return to Texas after fighting in Iraq.

"Rob Brown is an outstanding role model and a compassionate spokesperson for our cause," said Nancy Klein, senior vice president, LLS Marketing Communications. "His involvement with Light The Night and The Express will go a long way toward raising awareness about the urgency of finding cures and better treatments."

Light the Night Walk events are taking place in your community. For more information about Light The Night, please visit http://www.lightthenight.org.

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society(R), headquartered in White Plains, NY, with 68 chapters in the United States and Canada, is the world's largest voluntary health organization dedicated to funding blood cancer research and providing education and patient services. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. Since its founding in 1949, the LLS has invested more than $550 million in research specifically targeting leukemia, lymphoma and myeloma. Last year alone, the LLS made 5.1 million contacts with patients, caregivers and healthcare professionals.

For more information about blood cancer, visit http://www.LLS.org or call the LLS Information Resource Center (IRC), a call center staffed by master's level social workers, nurses and health educators who provide information, support and resources to patients and their families and caregivers. IRC information specialists are available at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET.

Contact: Andrea Greif

914-821-8958

andrea.greif@lls.org


'/>"/>
SOURCE The Leukemia & Lymphoma Society
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Genetic Factors for Smoking Boost Chronic Bronchitis Risk
2. Genetic factors in smoking also increase risk of chronic bronchitis
3. Effect of tumor necrosis factor a inhibitors on heart failure risk in RA Patients
4. NIH awards OHSU researcher $1.2 million to determine causes of, risk factors for pelvic floor injury
5. More Risk Factors, Less Access to Care Behind Higher Stroke Rates in U.S.
6. Stroke Risk Factors Drain Memory
7. Hormone refractory prostate cancers more likely to spread to other organs
8. TrailBlazer Announces Final Medicare Administrative Contractor Schedule for Claims Processing in Four States
9. Arizona State bioethicist says mental illness is subject to biological and sociocultural factors
10. PTSD a Risk Factor for Long-Term Disease
11. Bioniche Provides Update on Refractory Bladder Cancer Trial with Urocidin(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... A new ... with severe congenital diaphragmatic hernia have better survival rates if surgery is performed ... (CDH)—a condition where the diaphragm fails to form completely, letting abdominal organs into ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... won the $30,000 Perlman Grand Prize of the 2016 Wharton Business Plan ... the Michelson People’s Choice Award, and the Committee Award for Most ‘Wow Factor,’ ...
(Date:4/29/2016)... NY (PRWEB) , ... April 29, 2016 , ... ... and engineer of patented products, announces the Gyrociser, an exercise invention which aids ... worth $2 billion," says Scott Cooper, CEO and Creative Director of World Patent ...
(Date:4/29/2016)... ... April 29, 2016 , ... Melanoma is the deadliest type of skin cancer. Although only about ... of skin cancer deaths. More than 10,000 people are expected to die of melanoma this ... it is the one of the most commonly diagnosed cancers in young women. A recent ...
(Date:4/29/2016)... ... , ... New York City based oral and maxillofacial surgeon Dr. Majid Jamali is ... treat obstructive sleep apnea. Dr. Jamali is proud to offer this permanent solution to patients ... or both jaw bones. This surgery is performed to correct the alignment of the jaw. ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... April 28, 2016 New ... 2016" is a report that provides an overview ... R&D pipelines by identifying new targets and MOAs ... Company Profiles discussed in this H1 2016 Osteoarthritis ... Srl, AbbVie Inc., Abiogen Pharma S.p.A., Ablynx NV, ...
(Date:4/27/2016)... 2016 Im ... Zürich gab Strekin AG den Start einer ... Erhaltung des Resthörvermögens von Patienten, denen ein ... umfassende Phase-II-Doppelblindstudie mit Placebo-Kontrollgruppe werden momentan Patienten ... während der Operation direkt ins Mittelohr verabreicht. ...
(Date:4/27/2016)... , April 27, 2016 ... Including 42% Growth in Recurring Consumable Sales  ... Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor ... announced its sales for the first quarter ended March ... and the execution of its commercial strategy. ...
Breaking Medicine Technology: